AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$RVTY

Revvity (RVTY) Q3 2026 Earnings Call Transcript

Revvity (RVTY) reported Q3 2026 earnings, highlighting AI-driven demand growth across its portfolio, including high-content screening, life sciences reagents, and detection instruments. The company expects 5% full-year organic growth and adjusted EPS of $5.40-$5.45, up from initial forecasts. Revvity also launched new AI-native offerings in its signals software business and a new diagnostic kit for early type 1 diabetes detection in Europe.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity (RVTY) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The raised guidance suggests stronger revenue growth and margin expansion, likely supporting a price rally.

02

Market read

New earnings guidance for a mid‑cap biotech equipment firm provides a clear trading catalyst.

03

What to watch

Potential headwinds from the China immunodiagnostics divestiture and macro slowdown.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Revvity's Q3 earnings call highlighted AI‑driven demand, new product launches, and a revised full‑year EPS outlook.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity disclosed Q3 2026 results and raised full-year EPS guidance to $5.40‑$5.45, indicating stronger growth.

Expected impact

upward pressure as market prices in stronger full-year EPS guidance

Evidence & confidence

The new EPS range and 12% YoY growth outlook are materially better than prior guidance, prompting buying interest.

Market effects

Sector

Positive for life‑sciences reagents and AI‑enabled instrumentation sector.

Regional

U.S. biotech and technology stocks may see modest gains.

Global

Limited to investors tracking AI‑driven scientific equipment markets.

Counterpoint

What could challenge this read

If the AI demand does not materialize as projected, the guidance may be overly optimistic.

Key entities

  • company
    Revvity

    Life‑sciences and diagnostics equipment provider (ticker RVTY).

Read at source← All news

StoryRevity reports Q3 2026 earnings beat and lifts full‑year revenue and EPS outlook

Also covered by

4 outlets

Related articles

NOV 4
$RVTYHighAI 8/10

Revvity Q3 Earnings Call Highlights

Revvity reported Q3 earnings, highlighting AI-driven demand growth in high-content screening instruments, with revenue up 4% and backlog expansion across categories. Diagnostics revenue reached $330M, with mid-single-digit growth. The company raised its 2026 organic growth outlook to 5% and expects Q4 revenue of ~$755M. Margins improved, and free cash flow was strong. Revvity plans to discuss its AI strategy and outlook at an Investor Day event.

finance.yahoo.com2 min
NOV 3
$RVTYMedAI 8/10

Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth

Revvity Inc (RVTY) reported Q3 2026 earnings, highlighting 7% organic growth but guiding Q4 growth down to 5% due to lower reagent and software growth. APAC saw a low single-digit decline, and China's immunodiagnostics business remains a margin headwind. Software growth is expected to moderate, and AI demand is emerging but not yet quantified. The company confirmed sustainable incremental margins in the low 40s and expects a durable pharma biotech recovery.

finance.yahoo.com3 min
NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min